Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Ronald Mandel
University of Florida, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Lacerta Therapeutics, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
At the University of Florida, Dr. Ronald Mandel is a Professor in the Department of Neuroscience and is a Principal Investigator on research studies. Dr. Mandel owns approximately (b)(4) of the stock in Lacerta Therapeutics, Inc. and serves as member of the Board of Directors for the company. At times, Dr. Mandel engages in research that relates to Lacerta Therapeutics, Inc.’s AAV Vector interests. Lacerta Therapeutics, Inc. is interested in use of AAV vectors in the treatement to target AADC deficiency, SCA, MPS IIIB deficiency, and Alheimer’s disease. Lacerta Therapeutics, Inc. can be affected by the research funded by NIH because of using similar AAV vectors .
Optimizing AAV Vectors for Central Nervous System transduction
Project Narrative The goals of this research are to improve on current CNS-directed gene therapy approaches for Sanfilippo Syndrome and neurodegenerative diseases in general by comparing 40 promising vectors directly and confirming the cell type and expression levels of the best vectors in murine and primate models. The efficacy of the best vector will then be assessed in the murine model of Mucopolysaccharidosis type IIIB (MPS IIIB or Sanfilippo Syndrome type B). This disease has a devastating impact on the children and families affected and this proposal will identify an optimal therapy to relieve this disease burden.
Filed on December 01, 2017.
Tell us what you know about Ronald Mandel's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Ronald Mandel”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Ronald Mandel | University of Florida | Financial Disclosure | Johnson and Johnson | |
| Ronald Mandel | University of Florida | Financial Disclosure | NIH Center for Scientific review | |
| Ronald Mandel | University of Florida | Financial Disclosure | Amicus Therapeutics | |
| Ronald Mandel | University of Florida | Financial Disclosure | NIH Center for Scientific review |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.